Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Thompson

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|December 1, 2012
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populationsJawad Francis, Avinash V Dharmadhikari, Sheila N J Sait, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2018
Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagyArthur F Kluge, Bharat R Lagu, Pranab Maiti, et al.
Postgraduate Medical Journal|February 12, 2011
Using the ISBAR handover tool in junior medical officer handover: a study in an Australian tertiary hospitalJames E Thompson, Luke W Collett, Marc J Langbart, et al.
Leukemia Research Reports|May 3, 2017
Dexrazoxane for cardioprotection in older adults with acute myeloid leukemiaPankit Vachhani, Sarah Shin, Jeffrey Baron, et al.
American Journal of Hematology|March 27, 2015
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years oldNeha Gupta, Austin Miller, Shipra Gandhi, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2010
Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitorsRobert M Tynebor, Meng-Hsin Chen, Swaminathan R Natarajan, et al.
Leukemia Research|November 17, 2018
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experiencePankit Vachhani, Raed Al Yacoub, Austin Miller, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2010
Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1Robert M Tynebor, Meng-Hsin Chen, Swaminathan R Natarajan, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2012
Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2Robert M Tynebor, Meng-Hsin Chen, Swaminathan R Natarajan, et al.
Biotechniques|March 30, 2007
Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samplesMichael Liew, Matthew C Groll, James E Thompson, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|December 1, 2012
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populationsJawad Francis, Avinash V Dharmadhikari, Sheila N J Sait, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2018
Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagyArthur F Kluge, Bharat R Lagu, Pranab Maiti, et al.
Postgraduate Medical Journal|February 12, 2011
Using the ISBAR handover tool in junior medical officer handover: a study in an Australian tertiary hospitalJames E Thompson, Luke W Collett, Marc J Langbart, et al.
Leukemia Research Reports|May 3, 2017
Dexrazoxane for cardioprotection in older adults with acute myeloid leukemiaPankit Vachhani, Sarah Shin, Jeffrey Baron, et al.
American Journal of Hematology|March 27, 2015
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years oldNeha Gupta, Austin Miller, Shipra Gandhi, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2010
Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitorsRobert M Tynebor, Meng-Hsin Chen, Swaminathan R Natarajan, et al.
Leukemia Research|November 17, 2018
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experiencePankit Vachhani, Raed Al Yacoub, Austin Miller, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2010
Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1Robert M Tynebor, Meng-Hsin Chen, Swaminathan R Natarajan, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2012
Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2Robert M Tynebor, Meng-Hsin Chen, Swaminathan R Natarajan, et al.
Biotechniques|March 30, 2007
Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samplesMichael Liew, Matthew C Groll, James E Thompson, et al.
Pageof 10